Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.
about
Anti-hepatitis C virus drugs and kidneyHepatitis C Therapy in Renal Patients: Who, How, When?Direct-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney diseaseHepatitis C in a New Era: A Review of Current TherapiesEfficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis.Management of hepatitis C genotype 4 in the directly acting antivirals era.The HCV Treatment Revolution Continues: Resistance Considerations, Pangenotypic Efficacy, and Advances in Challenging Populations.Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection.Interferon-free regimens in patients with hepatitis C infection and renal dysfunction or kidney transplantationIs it time to rethink combined liver-kidney transplant in hepatitis C patients with advanced fibrosis?Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan.The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation.Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America.Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry.Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review.Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients.Special populations: treating hepatitis C in patients with decompensated cirrhosis and/or advanced renal impairment.Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment.Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience.Treatment Options in Hepatitis C.Clinical Pharmacokinetics of Dasabuvir.Opportunities for treatment of the hepatitis C virus-infected patient with chronic kidney disease.Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis.Treatment of HCV in Renal Disease: Subtle Management Considerations in the Era of Direct-acting Antivirals.Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis.The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir-based regimens.Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment.Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure.Iatrogenic Cushing Syndrome from Interaction Between Ritonavir and Oral Budesonide During Direct Acting Antiviral Hepatitis C TherapySafety and effectiveness of response-guided therapy using pegylated interferon and ribavirin for chronic hepatitis C virus infection in patients on maintenance dialysis.Sustained virological response to ombitasvir/paritaprevir/ritonavir and dasabuvir treatment for hepatitis C: Real-world data from a large healthcare provider.Long-term Patient and Graft Survival of Kidney Transplant Recipients with Hepatitis C Virus Infection in the United States.Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection in end stage renal disease patients: A prospective observational study.When and how can nephrologists treat hepatitis C virus infection in dialysis patients?Effect of Hepatitis C Treatment with Ombitasvir/Paritaprevir/R + Dasabuvir on Renal, Cardiovascular and Metabolic Extrahepatic Manifestations: A Post-Hoc Analysis of Phase 3 Clinical Trials.Grazoprevir plus elbasvir and other treatment options in hepatitis C infected patients with stage 4-5 chronic kidney disease.Contemporary Management of Hepatitis C in Patients with CKD.Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review.Recommendations for the treatment of hepatitis C virus infection in chronic kidney disease: a position statement by the Spanish association of the liver and the kidney.
P2860
Q28070279-B1EB863F-D928-40D5-B826-C95746FA8161Q28077130-7439BFD5-9E6E-427B-A49A-0A79F21F3C0EQ28077263-D3A7860F-FA44-4410-B1B0-03FDA7652DE6Q33585021-91B8AF6A-310E-4C73-90A0-CE67C5E5D3BCQ36220536-37AF5273-3818-4E02-8A07-CB8E0AC87251Q37312151-AD9CB6A5-3D0F-47B4-B937-A64841163089Q37555313-10ABDAD8-3D7C-45EE-B1D3-1E4596DB49D6Q37563692-BFEF5EA2-CE67-4AE6-A2E1-55C0E65A9E4FQ37628539-427E8556-517F-4E5E-9846-5B6D3833D071Q37651918-BC6F1401-F08E-496D-9EEC-B7CC5EC3849AQ38755098-C88D45A8-AE0F-4990-B89E-A0777E76CFB1Q38757351-0E3E3B6D-E320-4212-9BC4-92FA0B9F4491Q38859560-CE87ADAA-B770-40EF-AF07-4AED8343B3FCQ38876972-D8D18B57-0B59-45E7-AB5C-D6AC3489F1D6Q38893244-5D91EDEC-5757-409D-B54A-DC05933CCBD4Q38975165-667B8BCB-A93F-41EE-AD7C-560BEDA0DB9FQ39067369-33E1BE63-2145-41A1-818A-418AD783A8F8Q39092977-14652D32-2011-42A9-8B8D-8DDAE282031CQ39099569-3DD7C97A-42AF-47E5-AE3F-036CD8245E7AQ39112237-BF4AE326-E7EA-40C0-B3C9-1580A595730AQ39160612-15EA8B42-816B-40B7-ABFD-079A3D756B1AQ39455853-A4F71FF4-4CFA-430E-8BBD-01E1E974C69FQ40089989-671E1D53-FB17-4B29-9670-8FCE6C53E411Q40171525-9FF9C765-A1EB-4DDB-9C0E-2619F0C8B959Q40211449-106CDD1D-B113-40F2-8F97-A1567316A704Q40215846-F7979023-CC70-47D6-B279-EBCBBAAE07ACQ40278746-C26B90A8-BC83-48E8-95C4-C6F41B148D50Q40413390-1B5FAF42-C2CB-49AA-BF07-8505F78CB403Q40476119-EF58311E-C642-4EFF-B392-D24E64A466ACQ40539589-3BA17722-BE66-4D82-93DF-67CF01541819Q40707781-BED790F2-540E-4DF9-8E51-92A392FB2C31Q41923104-AF3EAAEA-1EFA-4883-9309-EFA0BB28A910Q41924793-658422F5-5736-4E78-ACB6-287384CD030DQ41925546-2ACA7028-0058-4CB4-8DEB-DC957E1A6E3AQ41934901-F67E55A1-BCA3-4391-B697-8FD2DD103BB5Q41995030-82DAD566-573F-4609-A757-94F4AEFBE2EAQ42370354-403D7435-C30B-4ED2-8F2D-41BCA898F784Q43041968-096AB78B-E06D-45DE-B876-DEBC5F00D5D2Q45324737-9F5D7112-B61B-4396-A1F3-E03E4966E1ACQ45325791-0D9D7E58-11A3-42CB-9E16-FF6611297D83
P2860
Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Efficacy of Direct-Acting Anti ...... nt or End-Stage Renal Disease.
@en
Efficacy of Direct-Acting Anti ...... nt or End-Stage Renal Disease.
@nl
type
label
Efficacy of Direct-Acting Anti ...... nt or End-Stage Renal Disease.
@en
Efficacy of Direct-Acting Anti ...... nt or End-Stage Renal Disease.
@nl
prefLabel
Efficacy of Direct-Acting Anti ...... nt or End-Stage Renal Disease.
@en
Efficacy of Direct-Acting Anti ...... nt or End-Stage Renal Disease.
@nl
P2093
P1433
P1476
Efficacy of Direct-Acting Anti ...... nt or End-Stage Renal Disease.
@en
P2093
Amit Khatri
Daniel E Cohen
David E Bernstein
Eric Cohen
Eric Lawitz
Manal Abunimeh
Mark S Sulkowski
Michael Bennett
Nancy S Shulman
P304
P356
10.1053/J.GASTRO.2016.02.078
P407
P577
2016-03-11T00:00:00Z